Significant improvement in overall survival (OS) results seen in phase 3 TROPiCS study. Sacituzumab Govitecan improved OS from 11.2 months to 14.4 months compared to treatment of choice chemo.
Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships ...
